Delta4’s Year in Review: Strong Momentum in 2025 Fuels Ambitious Plans for 2026
As 2025 draws to a close, Delta4 reflects on a remarkable year of scientific achievement, strategic partnerships, and technological advancement. From securing national recognition to publishing cutting-edge research and advancing major EU initiatives, Delta4 has demonstrated that AI-powered drug discovery, grounded in rigorous computational biology, is not only possible but scalable and impactful. “2025 has […]
Delta4 Advances Kidney Health with ADPKD Research & Partnerships
We are excited to share several important milestones that reflect our ongoing commitment to kidney health: advancing a new research collaboration with the Medical University of Innsbruck supported by the FFG Austrian Research Promotion Agency, joining the Signals Directory (Kidneyverse), and highlighting a valuable toolkit from the International Society of Nephrology (ISN) to raise awareness […]
Delta4 Showcase: From Neurotoxicity to Neuroprotection – A Collaborative Approach to Targeting Reactive Astrocytes
We’re excited to present a major milestone in our collaboration with Concept Life Sciences: our joint poster presentation at this year’s BNA2025, one of Europe’s largest neuroscience gatherings, bringing together thousands of researchers and industry leaders. This project combines the strengths of Concept Life Sciences’ neuroscience team with Delta4’s computational modeling to take on a […]
Delta4 At BIO-Europe
Delta4 Reflects on a Milestone BIO-Europe Spring 2025 in Milan Delta4 is pleased to share highlights from this year’s BIO-Europe Spring 2025, held in Milan, Italy—an event that marked our most successful participation to date. Representing Delta4 were Kurt Herpel (CEO) and Klaus Kratochwill (CSO), who spent two fully packed days in one-on-one meetings with […]
Delta4: A Trusted Partner in EU Horizon Research Projects
Delta4 is proud to announce its participation in two significant EU Horizon research projects: PICKED (Personalized Medicine in Chronic Kidney Disease) and PROMOTE (Prostate Cancer Omics Mediated Intervention). Horizon Europe is the world’s largest research funding program, focusing on advancing health, biomedical research, data science, and AI/ML. With a total budget of nearly EUR 100 […]
Delta4 Featured in the Finanz und Wirtschaft (FuW)
Delta4 is honored to have been featured in a recent article by Finanz und Wirtschaft, highlighting our pioneering work in AI-driven drug repurposing. The article sheds light on how our AI-powered platform, Hyper-C, identifies novel therapeutic uses for existing drugs, offering hope for more efficient and effective treatment strategies for a range of complex conditions. […]
Biomedical Knowledge Graphs for Drug Discovery: Delta4’s Innovative Approach
The term “knowledge graph” describes the process of storing data in a graph-structured topology. A graph database consists of three main elements: nodes, edges, and properties. Nodes symbolize instances or entities, such as proteins, diseases, or tissues. Edges, otherwise known as relationships, provide a contextual connection between nodes. Properties, on the other hand, enrich both […]
Pioneering the Future of Nephrotic Syndrome Research with ARREST-NEPHROSIS
Nephrotic Syndrome affects millions globally, presenting a significant health burden with its hallmark symptoms of severe proteinuria and edema. The quest for advanced treatments underscores the crucial role of biobanks and registries, which are instrumental in propelling medical research and innovation. At the forefront of this effort is ARREST-NEPHROSIS, an Austrian registry that exemplifies how […]
Digital Health Envision Summit
We are delighted to announce that Dr. Klaus Kratochwill, CSO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are looking forward to attending the prestigious 2023 Digital Health Envision Summit to be held in London, UK. The summit, renowned for being a hub of innovation in healthcare and neurology, aligns seamlessly with Delta4’s mission […]
Case Study: Unravelling the Multifaceted Potential of Iguratimod with Delta4’s Hyper-C Platform
Diving deep into the realms of computational drug repurposing, Delta4 leveraged its state-of-the-art Hyper-C platform with an ambitious objective: to comprehensively understand and broaden the applications of the anti-inflammatory compound iguratimod. At the heart of this project was the creation of a molecular Mechanism of Action (MoA) model. This intricate model was meticulously constructed around […]